The mechanism underlying 1-MNA activity is mainly based on regulating vascular endothelial function and maintaining the balance of its secretory functions. The endothelial cells which line the blood vessels not only channel blood throughout the body, but exert remarkable control over the entire vascular system. In fact, the endothelium acts as a highly active metabolic and endocrine organ. The proper function of this biggest secretory organ is therefore important to maintaining a healthy cardiovascular system.
Endothelial dysfunction leads to disruption in its functional balance and contributes to the development of various cardiovascular diseases, cardiovascular complications, as well as contributes to conditions in other organ systems leading to diseases such as diabetes, as well as gastrointestinal, hepatic and renal diseases. 1-MNA, through its actions on the cells of the vascular endothelium, stimulates these cells to release endogenous prostacyclin (PGI2), which stands as the strongest physiological blood platelet aggregation inhibitor. PGI2 has anticoagulant properties, along with anti-atherosclerotic properties. Its deficiency results in increased platelet aggregation and the creation of blood clots in arteries. PGI2 may also be responsible for lowering pro-inflammatory cytokine blood levels.
By stimulating endothelial cells to produce PGI2, 1-MNA reduces the level of inflammatory markers (high sensitivity C-reactive protein; hsCRP, Tumour Necrotic Factor-α; TNF-α, interleukin 4; IL-4) and contributes to cardiovascular system protection against the creation of blood clots, vascular atherosclerosis and the development of inflammation, as well as their related diseases.
1-MNA stands as an innovative molecule, patent protected globally.